Oyekoya T. Ayonrinde, John K. Olynyk, Lawrence J. Beilin, Trevor A. Mori, Craig E. Pennell, Nicholas de Klerk, Wendy H. Oddy, Peter Shipman, Leon A. Adams – 6 December 2010 – Nonalcoholic fatty liver disease (NAFLD) is a predominantly adult‐diagnosed disorder. Knowledge regarding the epidemiology, phenotype, and metabolic risk factors, during adolescence is limited.
Marie‐Luise Berres, Christian Trautwein, Maximilian Schmeding, Dennis Eurich, Frank Tacke, Marcus Bahra, Peter Neuhaus, Ulf P. Neumann, Hermann E. Wasmuth – 6 December 2010 – The recurrence of liver fibrosis after liver transplantation (LT) for hepatitis C virus (HCV) infection is responsible for graft loss and patient mortality. Although the contribution of the immune system to fibrosis recurrence is anticipated, systematic studies evaluating immune parameters as predictive markers of allograft fibrosis are lacking.
Catherine Rongey, Hal F. Yee – 6 December 2010
Marco Senzolo, Maria T. Sartori, Kryssia Rodriguez‐Castro, Paolo Simioni, Valeria Rossetto – 6 December 2010
Daniela E. Oprea‐Lager, Bastiaan J. Sorgdrager, J. Wouter Jukema, Roderick W. C. Scherptong, Jan Ringers, Minneke J. Coenraad, Bart van Hoek, Marcel P. M. Stokkel – 3 December 2010 – A cardiac evaluation before orthotopic liver transplantation (OLT) is imperative. Previous investigations have demonstrated that mild to moderate reversible perfusion defects on myocardial perfusion scintigraphy (MPS) in general are associated with a low risk for perioperative cardiac events.
Shin Hwang, Chul‐Soo Ahn, Gi‐Won Song, Ki‐Hun Kim, Deok‐Bog Moon, Heung‐Bum Oh, Young‐Suk Lim, Han Chu Lee, Tae‐Yong Ha, Dong‐Hwan Jung, Young‐Hwa Chung, Sung‐Gyu Lee – 3 December 2010 – A considerable proportion of liver transplantation recipients who receive hepatitis B immunoglobulin (HBIG) monotherapy for hepatitis B virus (HBV) prophylaxis develop resistance to HBIG. We retrospectively assessed the efficacy of HBV prophylaxis in 1524 patients who received primary high‐dose HBIG monotherapy (n = 1463) or with a preemptive antiviral add‐on as secondary combination therapy (n = 61).
Paolo R. Salvalaggio, Nino Dzebisashvili, Kara E. MacLeod, Krista L. Lentine, Adrian Gheorghian, Mark A. Schnitzler, Samuel Hohmann, Dorry L. Segev, Sommer E. Gentry, David A. Axelrod – 3 December 2010 – Accurate assessment of the impact of donor quality on liver transplant (LT) costs has been limited by the lack of a large, multicenter study of detailed clinical and economic data.
Shari S. Rogal, Douglas Landsittel, Owen Surman, Raymond T. Chung, Anna Rutherford – 3 December 2010 – Depression is a common problem among patients awaiting organ transplantation, but little is known about the impact of depression and its treatment on the outcomes of liver transplantation. In this retrospective cohort analysis, we studied all patients over 18 years of age who underwent liver transplantation during a 5‐year period (2004‐2008) at a single center. Among 179 recipients, 65 patients had depression, as defined by a health care provider assessment, before transplantation.
Ana Moreno, Jesús Fortún, Javier Graus, Miguel A. Rodriguez‐Gandía, Carmen Quereda, María J. Pérez‐Elías, Javier Nuño, Philip Wikman, Santiago Moreno, Rafael Bárcena – 3 December 2010 – Statins are relatively safe first‐line agents to use in the setting of dyslipidemia associated with immunosuppressive therapy in subjects undergoing liver transplantation, and also in HIV‐infected patients with dyslipidemia due to antiretroviral drugs, especially ritonavir‐boosted protease inhibitors.
Dmitri Bezinover, Zakiyah Kadry, Paul McCullough, Patrick M. McQuillan, Todahiro Uemura, Kelli Welker, Andrea M. Mastro, Piotr K. Janicki – 3 December 2010 – The objectives of this prospective, observational study were (1) to determine whether a transplanted liver graft releases proinflammatory cytokines into the systemic circulation upon reperfusion and (2) to determine whether they contribute to any subsequent hemodynamic instability observed after graft reperfusion (if this release occurs).